Journal
DIABETOLOGIA
Volume 54, Issue 10, Pages 2494-2505Publisher
SPRINGER
DOI: 10.1007/s00125-011-2243-0
Keywords
Biomaterial; Biotechnology; Diabetes; Extrahepatic; Immunomodulation; Islet transplantation; Review; Scaffold; Tissue engineering; Tolerance
Categories
Funding
- NIH NIDDK [F30 DK846492, R21 EB009502, R01 EB009910, DP2 DK083099, U01 AI089316]
Ask authors/readers for more resources
The promise and progress of islet transplantation for treating type 1 diabetes has been challenged by obstacles to patient accessibility and long-term graft function that may be overcome by integrating emerging technologies in biomaterials, drug delivery and immunomodulation. The hepatic microenvironment and traditional systemic immunosuppression stress the vulnerable islets and contribute to the limited success of transplantation. Locally delivering extracellular matrix proteins and trophic factors can enhance transplantation at extrahepatic sites by promoting islet engraftment, revascularisation and long-term function while avoiding unintended systemic effects. Cell- and cytokine-based therapies for immune cell recruitment and reprogramming can inhibit local and systemic immune system activation that normally attacks transplanted islets. Combined with antigen-specific immunotherapies, states of operational tolerance may be achievable, reducing or eliminating the long-term pharmaceutical burden. Integration of these technologies to enhance engraftment and combat rejection may help to advance the therapeutic efficacy and availability of islet transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available